Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR1 |
| Variant | R250W |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | FGFR1 R250W lies within the D2-D3 linker region of the Fgfr1 protein (PMID: 23276709). R250W results in similar cell proliferation and viability levels to wild-type Fgfr1 in two different cell lines in culture in one study (PMID: 29533785), increased proliferation and anchorage-independent colony formation in another study (PMID: 40526877), decreased proliferation relative to wild-type Fgfr1 in a competition assay, and transformation activity similar to wild-type Fgfr1 in another study (PMID: 34272467), and therefore, its effect on Fgfr1 protein function is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR1 mutant FGFR1 R250W |
| Transcript | NM_023110.3 |
| gDNA | chr8:g.38424697G>A |
| cDNA | c.748C>T |
| Protein | p.R250W |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_023110 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716304.1 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716304.2 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| NM_023110.2 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| NM_001174063.2 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716303 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_047421570.1 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_017013221.1 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_017013222 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| NM_001174063.1 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716304 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| NM_023110.3 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| NM_001174063 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716303.3 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_006716303.4 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_017013221.2 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_017013222.2 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| XM_017013221 | chr8:g.38424697G>A | c.748C>T | p.R250W | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Fexagratinib (AZD4547) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Fexagratinib (AZD4547) inhibited viability of cells expressing FGFR1 R250W in culture (PMID: 40526877). | 40526877 |
| FGFR1 R250W | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited viability of cells expressing FGFR1 R250W in culture (PMID: 40526877). | 40526877 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) inhibited viability of cells expressing FGFR1 R250W in culture (PMID: 40526877). | 40526877 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR1 R250W | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) inhibited viability of cells expressing FGFR1 R250W in culture (PMID: 40526877). | 40526877 |